{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:44:47Z","timestamp":1791895487853,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220797\/Z\/20\/Z"],"award-info":[{"award-number":["220797\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["7200AA20C00017"],"award-info":[{"award-number":["7200AA20C00017"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Effective vaccines against malaria are urgently required. All components of the PfPCRCR complex are essential for erythrocyte invasion by\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    and are potential vaccine immunogens against blood-stage malaria. Of these, PfRH5 has progressed furthest in clinical development, while PfCyRPA also induces parasite growth-inhibitory antibodies. Here, we used direct nanoparticle coupling and structure-guided design to generate improved PfCyRPA-based immunogens. PfCyRPA is a six-bladed \u03b2-propeller. Blades 1 and 2 are exposed in the PfPCRCR complex and contain the epitopes of the most potent known growth-inhibitory antibodies. We therefore performed structure-guided design to generate a correctly folded, thermostable epitope mimic, PfCyRPA-EM, containing blades 1 and 2. In a pre-clinical model, PfCyRPA-EM elicited antibodies that inhibited parasite growth at lower concentrations than those elicited by PfCyRPA. In addition, the higher thermostability of PfCyRPA-EM and its improved expression as an I53-50 nanoparticle fusion make it well-suited for clinical development, alone or with other immunogens.\n                  <\/jats:p>","DOI":"10.1038\/s44321-026-00376-x","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:03:19Z","timestamp":1772445799000},"page":"873-890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Structure-guided design of a PfCyRPA-based vaccine against blood-stage malaria"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-2373","authenticated-orcid":false,"given":"Nawsad","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3817-0170","authenticated-orcid":false,"given":"Clare","family":"Wolfle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egle","family":"Butkeviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Quinkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd D W","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-1955","authenticated-orcid":false,"given":"Matthew K","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"376_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2019.05.025","volume":"178","author":"DGW Alanine","year":"2019","unstructured":"Alanine DGW, Quinkert D, Kumarasingha R, Mehmood S, Donnellan FR, Minkah NK, Dadonaite B, Diouf A, Galaway F, Silk SE et al (2019) Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies. Cell 178:216\u2013228.e221","journal-title":"Cell"},{"key":"376_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10:787\u2013796","journal-title":"Nat Rev Immunol"},{"key":"376_CR3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1126\/science.8248784","volume":"262","author":"MF Bachmann","year":"1993","unstructured":"Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM (1993) The influence of antigen organization on B cell responsiveness. Science 262:1448\u20131451","journal-title":"Science"},{"key":"376_CR4","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1016\/j.cell.2024.06.015","volume":"187","author":"JR Barrett","year":"2024","unstructured":"Barrett JR, Pipini D, Wright ND, Cooper AJR, Gorini G, Quinkert D, Lias AM, Davies H, Rigby CA, Aleshnick M et al (2024) Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype. Cell 187:4964\u20134980.e4921","journal-title":"Cell"},{"key":"376_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/vaccines12080859","volume":"12","author":"KH Bjornsson","year":"2024","unstructured":"Bjornsson KH, Bassi MR, Knudsen AS, Aves KL, Morella Roig E, Sander AF, Barfod L (2024) Leveraging immunofocusing and virus-like particle display to enhance antibody responses to the malaria blood-stage invasion complex antigen PfCyRPA. Vaccines 12:859","journal-title":"Vaccines"},{"key":"376_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep19234","volume":"6","author":"KD Brune","year":"2016","unstructured":"Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M (2016) Plug-and-display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci Rep 6:19234","journal-title":"Sci Rep"},{"key":"376_CR7","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1073\/pnas.1616903114","volume":"114","author":"I Campeotto","year":"2017","unstructured":"Campeotto I, Goldenzweig A, Davey J, Barfod L, Marshall JM, Silk SE, Wright KE, Draper SJ, Higgins MK, Fleishman SJ (2017) One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen. Proc Natl Acad Sci USA 114:998\u20131002","journal-title":"Proc Natl Acad Sci USA"},{"key":"376_CR8","doi-asserted-by":"publisher","first-page":"e21347","DOI":"10.7554\/eLife.21347","volume":"6","author":"L Chen","year":"2017","unstructured":"Chen L, Xu Y, Wong W, Thompson JK, Healer J, Goddard-Borger ED, Lawrence MC, Cowman AF (2017) Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA. eLife 6:e21347","journal-title":"eLife"},{"key":"376_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, Ouedraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S et al (2024) Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403:533\u2013544","journal-title":"Lancet"},{"key":"376_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09894-4","volume":"10","author":"AD Douglas","year":"2019","unstructured":"Douglas AD, Baldeviano GC, Jin J, Miura K, Diouf A, Zenonos ZA, Ventocilla JA, Silk SE, Marshall JM, Alanine DGW et al (2019) A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates. Nat Commun 10:1953","journal-title":"Nat Commun"},{"key":"376_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","volume":"17","author":"AD Douglas","year":"2015","unstructured":"Douglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, Bartholdson SJ, Diouf A, Miura K, Lambert LE, Ventocilla JA et al (2015) A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe 17:130\u2013139","journal-title":"Cell Host Microbe"},{"key":"376_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1615","volume":"2","author":"AD Douglas","year":"2011","unstructured":"Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, Wyllie DH, Crosnier C, Miura K, Wright GJ et al (2011) The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2:601","journal-title":"Nat Commun"},{"key":"376_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","volume":"22","author":"PE Duffy","year":"2024","unstructured":"Duffy PE, Gorres JP, Healy SA, Fried M (2024) Malaria vaccines: a new era of prevention and control. Nat Rev Microbiol 22:756\u2013772","journal-title":"Nat Rev Microbiol"},{"key":"376_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486\u2013501","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"376_CR15","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans PR, Murshudov GN (2013) How good are my data and what is the resolution? Acta Crystallogr D Biol Crystallogr 69:1204\u20131214","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"376_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-023-06856-1","volume":"625","author":"B Farrell","year":"2024","unstructured":"Farrell B, Alam N, Hart MN, Jamwal A, Ragotte RJ, Walters-Morgan H, Draper SJ, Knuepfer E, Higgins MK (2024) The PfRCR complex bridges malaria parasite and erythrocyte during invasion. Nature 625:578\u2013584","journal-title":"Nature"},{"key":"376_CR17","doi-asserted-by":"publisher","first-page":"e20383","DOI":"10.7554\/eLife.20383","volume":"6","author":"P Favuzza","year":"2017","unstructured":"Favuzza P, Guffart E, Tamborrini M, Scherer B, Dreyer AM, Rufer AC, Erny J, Hoernschemeyer J, Thoma R, Schmid G et al (2017) Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. eLife 6:e20383","journal-title":"eLife"},{"key":"376_CR18","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1093\/bioinformatics\/bts565","volume":"28","author":"L Fu","year":"2012","unstructured":"Fu L, Niu B, Zhu Z, Wu S, Li W (2012) CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics 28:3150\u20133152","journal-title":"Bioinformatics"},{"key":"376_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.molcel.2016.06.012","volume":"63","author":"A Goldenzweig","year":"2016","unstructured":"Goldenzweig A, Goldsmith M, Hill SE, Gertman O, Laurino P, Ashani Y, Dym O, Unger T, Albeck S, Prilusky J et al (2016) Automated structure- and sequence-based design of proteins for high bacterial expression and stability. Mol Cell 63:337\u2013346","journal-title":"Mol Cell"},{"key":"376_CR20","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1038\/s44321-024-00123-0","volume":"16","author":"TE Harrison","year":"2024","unstructured":"Harrison TE, Alam N, Farrell B, Quinkert D, Lias AM, King LDW, Barfod LK, Draper SJ, Campeotto I, Higgins MK (2024) Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5. EMBO Mol Med 16:2539\u20132559","journal-title":"EMBO Mol Med"},{"key":"376_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101654","volume":"5","author":"LDW King","year":"2024","unstructured":"King LDW, Pulido D, Barrett JR, Davies H, Quinkert D, Lias AM, Silk SE, Pattinson DJ, Diouf A, Williams BG et al (2024) Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies. Cell Rep Med 5:101654","journal-title":"Cell Rep Med"},{"key":"376_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner D, Afonine PV, Baker ML, Bunkoczi G, Chen VB, Croll TI, Hintze B, Hung LW, Jain S, McCoy AJ et al (2019) Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol 75:861\u2013877","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"376_CR23","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli J, Fiala B, Ols S, Perotti M, de van der Schueren W, Snijder J, Hodge E, Benhaim M, Ravichandran R, Carter L et al (2019) Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176:1420\u20131431.e1417","journal-title":"Cell"},{"key":"376_CR24","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.3389\/fimmu.2019.02931","volume":"10","author":"A Marini","year":"2019","unstructured":"Marini A, Zhou Y, Li Y, Taylor IJ, Leneghan DB, Jin J, Zaric M, Mekhaiel D, Long CA, Miura K et al (2019) A universal plug-and-display vaccine carrier based on HBsAg VLP to maximize effective antibody response. Front Immunol 10:2931","journal-title":"Front Immunol"},{"key":"376_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Crystallogr 40:658\u2013674","journal-title":"J Appl Crystallogr"},{"key":"376_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","volume":"2","author":"AM Minassian","year":"2021","unstructured":"Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, Loos C, Fallon JK, Michell AR, White MT et al (2021) Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med 2:701\u2013719.e719","journal-title":"Med"},{"key":"376_CR27","doi-asserted-by":"crossref","unstructured":"Natama HM, Salkeld J, Some A, Soremekun S, Diallo S, Traore O, Rouamba T, Ouedraogo F, Ouedraogo E, Dabone KCS et al (2024) Safety and efficacy of the blood-stage malaria vaccine RH5.1\/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children. Lancet Infect Dis 25:495\u2013506","DOI":"10.1016\/S1473-3099(24)00752-7"},{"key":"376_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00330-7","volume":"6","author":"B Nguyen","year":"2021","unstructured":"Nguyen B, Tolia NH (2021) Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6:70","journal-title":"NPJ Vaccines"},{"key":"376_CR29","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/ijms22041934","volume":"22","author":"QD Nguyen","year":"2021","unstructured":"Nguyen QD, Kikuchi K, Maity B, Ueno T (2021) The versatile manipulations of self-assembled proteins in vaccine design. Int J Mol Sci 22:1934","journal-title":"Int J Mol Sci"},{"key":"376_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28601-4","volume":"13","author":"RJ Ragotte","year":"2022","unstructured":"Ragotte RJ, Pulido D, Lias AM, Quinkert D, Alanine DGW, Jamwal A, Davies H, Nacer A, Lowe ED, Grime GW et al (2022) Heterotypic interactions drive antibody synergy against a malaria vaccine candidate. Nat Commun 13:933","journal-title":"Nat Commun"},{"key":"376_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386:31\u201345","journal-title":"Lancet"},{"key":"376_CR33","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/s41564-022-01261-2","volume":"7","author":"SW Scally","year":"2022","unstructured":"Scally SW, Triglia T, Evelyn C, Seager BA, Pasternak M, Lim PS, Healer J, Geoghegan ND, Adair A, Tham WH et al (2022) PCRCR complex is essential for invasion of human erythrocytes by Plasmodium falciparum. Nat Microbiol 7:2039\u20132053","journal-title":"Nat Microbiol"},{"key":"376_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.medj.2023.07.003","volume":"4","author":"SE Silk","year":"2023","unstructured":"Silk SE, Kalinga WF, Mtaka IM, Lilolime NS, Mpina M, Milando F, Ahmed S, Diouf A, Mkwepu F, Simon B et al (2023) Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. Med 4:668\u2013686.e667","journal-title":"Med"},{"key":"376_CR35","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S1473-3099(24)00312-8","volume":"24","author":"SE Silk","year":"2024","unstructured":"Silk SE, Kalinga WF, Salkeld J, Mtaka IM, Ahmed S, Milando F, Diouf A, Bundi CK, Balige N, Hassan O et al (2024) Blood-stage malaria vaccine candidate RH5.1\/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial. Lancet Infect Dis 24:1105\u20131117","journal-title":"Lancet Infect Dis"},{"key":"376_CR36","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls AC, Fiala B, Schafer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O\u2019Connor MA, Chen C et al (2020) Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183:1367\u20131382.e1317","journal-title":"Cell"},{"key":"376_CR37","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1016\/j.cell.2024.06.037","volume":"187","author":"LT Wang","year":"2024","unstructured":"Wang LT, Cooper AJR, Farrell B, Miura K, Diouf A, Muller-Sienerth N, Crosnier C, Purser L, Kirtley PJ, Maciuszek M et al (2024) Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5. Cell 187:4981\u20134995.e4914","journal-title":"Cell"},{"key":"376_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48721-3","volume":"15","author":"BG Williams","year":"2024","unstructured":"Williams BG, King LDW, Pulido D, Quinkert D, Lias AM, Silk SE, Ragotte RJ, Davies H, Barrett JR, McHugh K et al (2024) Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex. Nat Commun 15:4857","journal-title":"Nat Commun"},{"key":"376_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/pro.4224","volume":"31","author":"G Winter","year":"2022","unstructured":"Winter G, Beilsten-Edmands J, Devenish N, Gerstel M, Gildea RJ, McDonagh D, Pascal E, Waterman DG, Williams BH, Evans G (2022) DIALS as a toolkit. Protein Sci 31:232\u2013250","journal-title":"Protein Sci"},{"key":"376_CR30","unstructured":"World Health Organisation (2024) World Malaria Report. World Health Organisation"},{"key":"376_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature13715","volume":"515","author":"KE Wright","year":"2014","unstructured":"Wright KE, Hjerrild KA, Bartlett J, Douglas AD, Jin J, Brown RE, Illingworth JJ, Ashfield R, Clemmensen SB, de Jongh WA et al (2014) Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 515:427\u2013430","journal-title":"Nature"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00376-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:44:31Z","timestamp":1779065071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00376-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,13]]}},"alternative-id":["376"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00376-x","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA and MKH are named inventors on patent applications relating to PfCyRPA-EM and\/or other malaria vaccines, and immunisation regimes. NA, MKH, LDWK, and DQ are inventors on patent applications relating to RH5 malaria vaccines and\/or antibodies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}